BTIG Research Reiterates “Buy” Rating for Novavax (NASDAQ:NVAX)

Novavax (NASDAQ:NVAX)‘s stock had its “buy” rating reaffirmed by equities research analysts at BTIG Research in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $19.00 price target on the biopharmaceutical company’s stock. BTIG Research’s target price would suggest a potential upside of 91.92% from the stock’s current price.

A number of other brokerages also recently weighed in on NVAX. HC Wainwright upped their price target on shares of Novavax from $10.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. Cantor Fitzgerald initiated coverage on shares of Novavax in a research report on Friday, October 24th. They issued an “overweight” rating and a $18.00 price target on the stock. B. Riley reiterated a “buy” rating and set a $16.00 price objective (down previously from $18.00) on shares of Novavax in a research report on Monday, November 10th. Finally, TD Cowen decreased their target price on Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a report on Tuesday, November 4th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $11.25.

Novavax Price Performance

Shares of NASDAQ:NVAX opened at $9.90 on Tuesday. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of 5.53 and a beta of 2.37. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.27 and a quick ratio of 2.24. Novavax has a 12 month low of $5.01 and a 12 month high of $10.64. The stock’s 50 day moving average price is $7.06 and its 200 day moving average price is $7.69.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by ($0.17). The firm had revenue of $70.45 million for the quarter, compared to analyst estimates of $55.63 million. Novavax had a net margin of 32.10% and a negative return on equity of 217.02%. The firm’s revenue for the quarter was down 16.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.76) earnings per share. Equities research analysts anticipate that Novavax will post -1.46 earnings per share for the current fiscal year.

Institutional Trading of Novavax

A number of hedge funds have recently made changes to their positions in NVAX. AQR Capital Management LLC grew its position in Novavax by 95.2% during the first quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 21,663 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Novavax by 2.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock worth $678,000 after acquiring an additional 2,750 shares during the last quarter. Caxton Associates LLP purchased a new stake in shares of Novavax during the first quarter worth $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Novavax by 16.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company’s stock valued at $2,005,000 after purchasing an additional 44,105 shares during the last quarter. Finally, Strs Ohio purchased a new position in Novavax in the first quarter valued at about $167,000. 53.04% of the stock is owned by hedge funds and other institutional investors.

Novavax News Summary

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax signed a non‑exclusive license with Pfizer for Matrix‑M (up to two disease areas): $30M upfront, up to $500M in milestones and mid‑single‑digit royalties — a clear near‑term cash infusion and large upside if milestones are achieved. Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer
• Positive Sentiment: Market reacted positively to the Pfizer licensing news with shares trading up and headlines noting a pop after the announcement, reflecting short‑term investor enthusiasm. Novavax Pops on Pfizer Licensing Deal
• Positive Sentiment: Unusually large call‑option activity — about 24,027 calls traded (≈99% above typical call volume) — signals bullish positioning from options traders expecting further upside or volatility near catalysts. (no direct link)
• Positive Sentiment: Analyst support: BTIG reaffirmed a Buy with a $19 price target, highlighting upside versus current levels; H.C. Wainwright also reiterated a Buy, noting licensing expansion as a positive. Novavax: Expanding Matrix-M Licensing Partnerships Drive Upside Potential and Support Buy Rating
• Neutral Sentiment: Valuation and coverage pieces are circulating that reassess NVAX based on the Pfizer deal; these provide models but reach different conclusions depending on milestone probability assumptions. Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal
• Neutral Sentiment: Industry commentary explains Pfizer’s rationale for paying up for Matrix‑M and discusses how licensing fits broader vaccine strategies — useful context but not an immediate price driver. Here’s Why Pfizer Is Willing To Pay $500 Million For Novavax’s Matrix-M
• Negative Sentiment: Bank of America reiterated a Sell and flagged execution risks, long‑dated cash flows and COVID market headwinds—cautioning that milestone timing and pandemic vaccine demand could limit near‑term profitability; BofA set a $7 price target. Novavax: Execution Risks, Long-Dated Cash Flows, and COVID Market Headwinds Undermine Profitability Outlook

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.